Metformin in breast cancer: preclinical and clinical evidence
Metformin in breast cancer: preclinical and clinical evidence
复制标题
DOI：
10.1016/j.currproblcancer.2019.06.003
复制
发表时间：
2020-02-01
影响因子：
2.6
通讯作者：
Kuppusamy, Gowthamarajan
中科院分区：
文献类型：
--
作者：
De, Anindita;Kuppusamy, Gowthamarajan
二甲双胍是一种公认的双胍类、安全性和多作用药物，用于治疗2型糖尿病成本低，是再利用的首选药物。非专利药引起了巨大的关注，重新定位为抗癌药物输送最近。仍然有一些尚未回答的问题是具有挑战性的，其中一个主要问题是：二甲双胍能否作为所有乳腺癌亚型的通用疗法？二甲双胍能克服耐药性问题吗？该综述重点关注二甲双胍作用机制，特别是用于乳腺癌治疗和克服耐药性：还讨论了临床前和正在进行的以及已完成的临床试验。现有的局限性，如专门用于癌症治疗的治疗剂量，二甲双胍在乳腺癌中的耐药性和药物的有机阳离子转运蛋白异质性，为提高对乳腺癌的理解和成功应用开辟了一条新的途径。然而，还需要更多的研究来证实二甲双胍治疗预防癌症及其复发的准确疗效。(C)2019爱思唯尔公司All rights reserved.
Metformin, a well-acknowledged biguanide, safety profile and multiaction drug with low cost for management of type 2 diabetes, makes a first-class candidate for repurposing. The off-patent drug draws huge attention for repositioned for anticancer drug delivery recently. Still few unanswered questions are challenging, among them one leading question; can metformin use as a generic therapy for all breast cancer subtypes? And is metformin able to get over the problem of drug resistance? The review focused on the mechanisms of metformin action specifically for breast cancer therapy and overcoming the resistance: also discusses preclinical and ongoing and completed clinical trials. The existing limitation such as therapeutic dose specifically for cancer treatment, resistance of metformin in breast cancer and organic cation transporters heterogeneity of the drug opens up a new pathway for improved understanding and successful application as repurposed effective chemotherapeutics for breast cancer. However, much more additional research is needed to confirm the accurate efficacy of metformin treatment for prevention of cancer and its recurrence. (C) 2019 Elsevier Inc. All rights reserved.